What Is Up With DMPA And “Grades” For Family Planning?
This is an information sheet for consumers about the hormonal contraceptive known as Depo-Provera (DMPA) and the WHO grading system for contraceptives explains key issues in plain language.
Research findings have raised questions about the safety and effectiveness of DMPA for women who face a high risk of HIV. WHO evaluates the safety and efficacy of contraceptive methods. This sheet raises questions consumers may have about the relationship between hormonal contraceptives and HIV.
Date of Publication: March 25, 2019
- Hormonal Contraceptive Eligibility for Women at High Risk of HIV- FAQs
- Hormonal Contraception and HIV - Technical Update
- Hormonal Contraceptive Eligibility for Women at High Risk of HIV: Guidance Statement
- Contraception and HIV: What Do the Evidence and WHO Technical Statement Mean for Programs?
- Hormonal Contraception and HIV - Webinar
- Strategic Communication for Hormonal Contraception and HIV: An Evidence Review
- Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-Related Risks
- Hormonal Contraception and HIV: Putting New Developments in Context
- Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study
- Family Planning and HIV Service Integration E-Learning Course
- Hormonal Contraceptives and HIV – An Introductory Fact Sheet
- Thinking about Using Depo? Things to Consider
- Adapting the Framework: The Swaziland Experience
- Adaptation of Hormonal Contraceptive and HIV Communication Strategy in Malawi
- Hormonal Contraception and Potential HIV Risks - Frequently Asked Questions